top of page
News, Events and Updates
Search
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial
Feb 4, 2022
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Feb 1, 2022
Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD
Oct 13, 2021
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome
Aug 26, 2021
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Aug 12, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jul 28, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS
Jun 27, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial
Jun 20, 2021
Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Jun 13, 2021
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73
Jun 7, 2021
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73
Jun 3, 2021
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board
Apr 11, 2021
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board
Mar 30, 2021
Anavex Life Sciences Reports ANAVEX®2-73 featured as a Disease-Modifying Small Molecule in Trials
Mar 16, 2021
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data
Dec 21, 2020
Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial
Dec 15, 2020
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims
Nov 30, 2020
Anavex Life Sciences Presents Proof of Concept Controlled Phase 2 Clinical Trial Data
Nov 6, 2020
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Trial
Oct 14, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 9, 2020
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
